NDAINTRAVENOUSSOLUTION
Approved
Feb 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
PEMFEXY (pemetrexed) by Eagle Pharmaceuticals is folate-dependent metabolic processes essential for cell replication. Approved for non-small cell lung cancer, mesothelioma. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PEMFEXY (pemetrexed) is a folate antagonist small-molecule chemotherapy agent that inhibits thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase to disrupt nucleotide synthesis and cell replication. It is approved for non-small cell lung cancer and mesothelioma via intravenous infusion. The drug is indicated for patients with advanced or metastatic disease who have failed or are ineligible for first-line therapies.
Peak9.8 years to LOE
Product is at peak lifecycle stage with stable reimbursement; commercial teams likely focus on market maintenance and therapy optimization rather than growth expansion.
Mechanism of Action
folate-dependent metabolic processes essential for cell replication. In vitro studies show that pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in the de novo…
Indications (2)
Worked on PEMFEXY at Eagle Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.